Pay-for-delay concerns up again in Europe
This article was originally published in Scrip
The number of patent settlement deals signed between originator companies and generics manufacturers which may violate EU anti-competition rules tripled in 2011 over the previous year, according to the European Commission's third monitoring report. Of 120 patent settlements signed in the EU in 2011, 13 fell into the category of those which limit generic entry and involve value transfer from the originator company. This type of deal is "likely to attract the highest degree of antitrust scrutiny", according to the Commission.
You may also be interested in...
The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?
Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.